---
title: "Tyra Biosciences to present initial Phase 2 SURF302 data for oral dabogratinib in intermediate-risk bladder cancer on Sept. 9"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298034950.md"
description: "Tyra Biosciences will present initial Phase 2 SURF302 data for oral dabogratinib in intermediate-risk non-muscle invasive bladder cancer during a conference call on September 9, 2026. This early readout from the key clinical program targeting FGFR biology may influence future development decisions."
datetime: "2026-09-04T12:01:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298034950.md)
  - [en](https://longbridge.com/en/news/298034950.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298034950.md)
generator: "portal-rs"
---

# Tyra Biosciences to present initial Phase 2 SURF302 data for oral dabogratinib in intermediate-risk bladder cancer on Sept. 9

-   Tyra Biosciences scheduled a Sept. 9, 2026 conference call to present initial Phase 2 results for oral dabogratinib. \* Data will be presented in the future, covering the SURF302 study in intermediate-risk non-muscle invasive bladder cancer. \* The update signals an early readout for a key clinical program targeting FGFR biology, a potential driver of future development decisions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609040800PR\_NEWS\_USPR\_\_\_\_\_LA40038) on September 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [TYRA.US](https://longbridge.com/en/quote/TYRA.US.md)

## Related News & Research

- [Tyra Biosciences: Buy Rating Reiterated as SURF302 Data Upside Beckons; 12‑Month Price Target Maintained at $45](https://longbridge.com/en/news/298055291.md)
- [Mabwell reports Phase Ib/IIa data showing anti-ST2 antibody 9MW1911 cuts COPD exacerbations up to 81%](https://longbridge.com/en/news/298042457.md)
- [Nexstim receives order for additional NBS 6 therapy system from Nordic private clinic](https://longbridge.com/en/news/297867104.md)
- [Upstream Bio plans Q1 2027 start for Phase 3 verekitug trials in severe asthma, nasal polyps](https://longbridge.com/en/news/297641472.md)
- [Newmark Group announces R$ 0.1 dividend per unit for Q3 2026](https://longbridge.com/en/news/297698680.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**